<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474816</article-id><article-id pub-id-type="pmcid-ver">PMC12474816.1</article-id><article-id pub-id-type="pmcaid">12474816</article-id><article-id pub-id-type="pmcaiid">12474816</article-id><article-id pub-id-type="pmid">41003875</article-id><article-id pub-id-type="doi">10.1007/s12672-025-03558-0</article-id><article-id pub-id-type="publisher-id">3558</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Early antibiotic exposure does not affect prognosis in patients with advanced gastric cancer treated with PD-1 inhibitors</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Qu</surname><given-names initials="Z">Ziting</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yuyan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Z">Zhikun</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yiyin</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yan</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5800-5256</contrib-id><name name-style="western"><surname>Gu</surname><given-names initials="K">Kangsheng</given-names></name><address><email>gukangsheng@ahmu.edu.cn</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03t1yn780</institution-id><institution-id institution-id-type="GRID">grid.412679.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 1771 3402</institution-id><institution>Department of Oncology, </institution><institution>The First Affiliated Hospital of Anhui Medical University, </institution></institution-wrap>Hefei, Anhui Province China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>1719</elocation-id><history><date date-type="received"><day>2</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 14:25:15.427"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12672_2025_Article_3558.pdf"/><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">To explore the prognostic impact of antibiotic exposure during programmed death receptor-1 (PD-1) inhibitor therapy in patients with advanced gastric cancer (AGC).</p></sec><sec><title>Methods</title><p id="Par2">Data of 218 AGC patients treated with PD-1 inhibitors were retrospectively collected. The impact of antibiotic exposure in different time windows and other clinical factors on the prognosis of AGC patients was analyzed.</p></sec><sec><title>Results</title><p id="Par3">Antibiotic exposure prior to PD-1 inhibitor therapy (pATB) was significantly correlated with peritoneal metastasis (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007). Concurrent antibiotic exposure (cATB) was associated with different treatment types (<italic toggle="yes">P</italic>&#8201;=&#8201;0.012) and ECOG PS (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). In terms of prognosis, neither pATB nor cATB exposure significantly affected overall survival (OS) (<italic toggle="yes">P</italic>&#8201;=&#8201;0.804, <italic toggle="yes">P</italic>&#8201;=&#8201;0.324), whereas cATB exposure was a predictive factor for progression free survival (PFS) (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007). Treatment lines (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and cATB exposure (<italic toggle="yes">P</italic>&#8201;=&#8201;0.027) were independent prognostic variables for predicting PFS according to multivariate Cox analysis. Furthermore, it was found that treatment lines (<italic toggle="yes">P</italic>&#8201;=&#8201;0.004) and peritoneal metastasis (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002) were independent prognostic variables that predicted OS. However, in the sensitivity analysis, nine patients experienced varying degrees of delay in subsequent treatment after cATB exposure, leading to disease progression. Exclusion of these nine patients revealed that adjusted cATB exposure was not a prognostic factor for PFS in AGC patients (<italic toggle="yes">P</italic>&#8201;=&#8201;0.074).</p></sec><sec><title>Conclusion</title><p id="Par4">There is no evidence that antibiotics affect the long-term OS prognosis of AGC patients receiving PD-1 inhibitor therapy. Therefore, physicians should not delay PD-1 inhibitor combination treatment regimens in AGC patients who have recently received antibiotics.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-025-03558-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Antibiotics</kwd><kwd>Gastric cancer</kwd><kwd>PD-1 inhibitors</kwd><kwd>Prognosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Anhui Medical University Graduate Student Research and Practice Innovation Program</institution></funding-source><award-id>YJS20240020</award-id><principal-award-recipient><name name-style="western"><surname>Qu</surname><given-names>Ziting</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Basic and Clinical Collaborative Research Enhancement Project of Anhui Medical University</institution></funding-source><award-id>2023xkjT039</award-id><principal-award-recipient><name name-style="western"><surname>Zhang</surname><given-names>Yiyin</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>the Health Research Project of Anhui Province</institution></funding-source><award-id>AHWJ2023A10025</award-id><principal-award-recipient><name name-style="western"><surname>Gu</surname><given-names>Kangsheng</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Gastric cancer is one of the leading causes of cancer-related deaths worldwide, and advanced gastric cancer (AGC) patients have limited treatment options and low 5-year survival [<xref ref-type="bibr" rid="CR1">1</xref>]. Since immune checkpoint inhibitors (ICIs) were developed, the prognosis for AGC patients has significantly improved, particularly for those treated with inhibitors targeting the programmed cell death protein-1 (PD-1) [<xref ref-type="bibr" rid="CR2">2</xref>]. The prognosis of AGC patients can be considerably improved by combining chemotherapy and PD-1 inhibitors, according to several phase III clinical trials [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. However, the response rate of patients to PD-1 inhibitor therapy remains low, and only some patients can achieve durable clinical efficacy. Finding biomarkers and associated variables that may impact efficacy is therefore clinically critical.</p><p id="Par6">Emerging evidence implicates the gut microbiome as a pivotal modulator of systemic and anti-tumor immunity, fundamentally shaping host responses to ICIs [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. Antibiotic-induced dysbiosis has been associated with diminished ICIs efficacy across multiple malignancies including lung cancer, renal carcinoma and head/neck squamous cell carcinoma [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. This association holds biological plausibility in gastric cancer pathogenesis, where chronic Helicobacter pylori infection and inflammation-driven dysbiosis create a unique microenvironment that favors immune evasion [<xref ref-type="bibr" rid="CR5">5</xref>]. Despite this biological plausibility, the clinical impact of antibiotics on the prognosis of patients treated with ICIs remains under-explored.</p><p id="Par7">According to a recent study, older cancer patients who were exposed to antibiotics before receiving ICI therapy had a worse overall survival (OS) [<xref ref-type="bibr" rid="CR9">9</xref>]. Another study showed that exposure to antibiotics during the four weeks before to starting PD-1 treatment was a predictor of long-term survival for patients with gastric cancer [<xref ref-type="bibr" rid="CR10">10</xref>]. However, a recent study has come to the opposite conclusion, suggesting that prophylactic use of antibiotics is associated with better outcomes in GC patients receiving immunotherapy. Therefore, there is no need to delay the use of immune checkpoint inhibitors in GC patients [<xref ref-type="bibr" rid="CR11">11</xref>]. Notably, despite research demonstrating the possible influence of antibiotics on immunotherapy, the following important questions have not been addressed: First, antibiotic (ATB) exposure may interact with other clinical variables. There is insufficient adjustment for confounders, which reduces the credibility of the conclusions, and there is a lack of studies on AGC patients. Second, the critical time window for antibiotic exposure in AGC patients receiving PD-1 inhibitors has not been clarified. AGC is a malignant tumor with a unique immune microenvironment. The mechanistic link between antibiotic-induced dysbiosis and immune dysregulation in gastric cancer needs to be further elucidated.</p><p id="Par8">Therefore, this research systematically assessed the impact of antibiotic exposure and other clinical variables on the prognosis of PD-1 inhibitors in AGC patients using a retrospective cohort. The main points were as follows: (1) The correlation between antibiotic exposure and baseline clinical characteristics was analyzed. (2) The effects of ATB exposure on long-term survival in different time windows were analyzed. (3) The relevance of ATB exposure and other clinical features in the prognostic evaluation of AGC patients receiving PD-1 inhibitor treatment was investigated.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Patient collection</title><p id="Par9">A retrospective collection of 218 AGC patients who were hospitalized in the oncology-related departments from the First Affiliated Hospital of Anhui Medical University between July 17, 2019, and November 25, 2022, was performed. The patients received combined PD-1 inhibitor treatment during hospitalization.</p><p id="Par10">The following were the requirements for inclusion: (1) patients with advanced unresectable gastric cancer; (2) patients with physical conditions that could tolerate PD-1 inhibitor treatment; (3) patients with a complete antibiotic exposure record within a specified period of time; and (4) patients with complete clinicopathologic data who could be followed up regularly. The following were the requirements for exclusion: (1) incomplete clinical data for evaluation and follow-up; (2) any active autoimmune disease; (3) two or more primary malignancies, and (4) a medical condition that could not tolerate PD-1 inhibitor therapy. Prior to starting ICIs treatment, each patient signed an informed consent form. The Anhui Medical University&#8217;s Ethics Committee gave its approval to this study (Quick-PJ 2023-14-77).</p></sec><sec id="Sec4"><title>Delineation of the duration of antibiotic exposure</title><p id="Par11">Data were collected through the medical record system of the First Affiliated Hospital of Anhui Medical University to obtain records on the time of immunotherapy initiation, antibiotic initiation, and antibiotic use. Regarding the definition of the antibiotic window period, researches reported that the recovery of the microbiome after antibiotic treatment takes 6&#8211;8 weeks [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Based on previous researches, we systematically divided the time of antibiotic exposure into different time windows [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], which can be categorized as follows: (1) ATB exposure from 60 days before PD-1 inhibitor treatment to 30 days before treatment; (2) ATB exposure from 30 days before PD-1 inhibitor treatment to 1&#160;day before treatment; (3) ATB exposure from 1&#160;day after PD-1 inhibitor treatment to 30 days after treatment; (4) ATB exposure from 30 days after PD-1 inhibitor treatment to 60 days after treatment; (5) ATB exposure from 60 days before PD-1 inhibitor treatment to 1&#160;day before treatment (pATB); and (6) ATB exposure from 1&#160;day after PD-1 inhibitor treatment to 60 days after treatment (cATB).</p></sec><sec id="Sec5"><title>Efficacy evaluation and survival follow-up</title><p id="Par12">The effectiveness assessment was conducted using the Response Evaluation Criteria for Solid Tumors 1.1 (RECIST1.1), and the survival follow-up was conducted over the phone or using an electronic medical record system. OS and progression free survival (PFS) were the study&#8217;s main endpoints. PFS was defined as the interval between the onset of PD-1 inhibitor treatment and the date of the patient&#8217;s death, last follow-up, or disease progression. OS was defined as the interval between the day they began using PD-1 inhibitors and patient&#8217;s death or last follow-up. The final follow-up cutoff date was December 1, 2023.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par13">Fisher&#8217;s exact test or the chi-square test was used to compare qualitative variables. The Kaplan-Meier curves were used to plot survival curves, and the Log-rank test was used to evaluate them. To find prognostic factors, univariate and multivariate Cox regression analysis with 95%CI were conducted. In order to create the final multivariate model, factors with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 were included using a stepwise backward procedure based on all variables with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 in the univariate Cox regression analysis. For every test, a two-sided <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 was deemed statistically significant. The SPSS (version 26.0) and R software (version 4.1.2) were used to conduct statistical analyses.</p></sec></sec><sec id="Sec7"><title>Rusults</title><sec id="Sec8"><title>Relationship between characteristics and antibiotic exposure</title><p id="Par14">The cohort in our study comprised 218 patients diagnosed with advanced gastric cancer (AGC) who had undergone PD-1 inhibitor combination therapy between July 17, 2019, and November 25, 2022. Of these patients, 66 had been exposed to antibiotics within 60 days before starting PD-1 inhibitor treatment (pATB), and 52 had concurrent antibiotic exposure (cATB) within 60 days of starting treatment. Table&#160;<xref rid="Tab1" ref-type="table">1</xref> displays the baseline demographic parameters. In particular, we found a strong correlation between the peritoneal metastasis and exposure to pATB (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007). Moreover, cATB exposure was correlated with different treatment types (<italic toggle="yes">P</italic>&#8201;=&#8201;0.012) and Eastern Cooperative Oncology Group performance status (ECOG PS) (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). Antibiotic exposure was not significantly associated with any other clinical characteristic. Then, we analyzed the antibiotic usage among 218 patients, with 88 patients having used antibiotics (Table S1). Among these, 21 patients used penicillins, 58 used cephalosporins, 35 used quinolones, 19 used nitroimidazoles, 5 used aminoglycosides, and 5 used other types of antibiotics. Among these, 48 patients used only one type of antibiotic, while 40 patients used two or more types of antibiotics.</p><p id="Par15">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Patient demographics and baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="left" colspan="3" rowspan="1">pATB exposure</th><th align="left" colspan="3" rowspan="1">cATB exposure</th></tr><tr><th align="left" colspan="1" rowspan="1">No, <italic toggle="yes">N</italic>&#8201;=&#8201;152<sup>1</sup></th><th align="left" colspan="1" rowspan="1">Yes, <italic toggle="yes">N</italic>&#8201;=&#8201;66<sup>1</sup></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value<sup>2</sup></th><th align="left" colspan="1" rowspan="1">No, <italic toggle="yes">N</italic>&#8201;=&#8201;166<sup>1</sup></th><th align="left" colspan="1" rowspan="1">Yes, <italic toggle="yes">N</italic>&#8201;=&#8201;52<sup>1</sup></th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value<sup>2</sup></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.053</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.058</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td char="." align="char" colspan="1" rowspan="1">110 (72.4%)</td><td char="." align="char" colspan="1" rowspan="1">39 (59.1%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">119 (71.7%)</td><td char="." align="char" colspan="1" rowspan="1">30 (57.7%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td char="." align="char" colspan="1" rowspan="1">42 (27.6%)</td><td char="." align="char" colspan="1" rowspan="1">27 (40.9%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">47 (28.3%)</td><td char="." align="char" colspan="1" rowspan="1">22 (42.3%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age (years)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.180</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.990</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;65</td><td char="." align="char" colspan="1" rowspan="1">89 (58.6%)</td><td char="." align="char" colspan="1" rowspan="1">45 (68.2%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">102 (61.4%)</td><td char="." align="char" colspan="1" rowspan="1">32 (61.5%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;65</td><td char="." align="char" colspan="1" rowspan="1">63 (41.4%)</td><td char="." align="char" colspan="1" rowspan="1">21 (31.8%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">64 (38.6%)</td><td char="." align="char" colspan="1" rowspan="1">20 (38.5%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Peritoneal metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">
<bold>0.007</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.160</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td char="." align="char" colspan="1" rowspan="1">119 (78.3%)</td><td char="." align="char" colspan="1" rowspan="1">40 (60.6%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">125 (75.3%)</td><td char="." align="char" colspan="1" rowspan="1">34 (65.4%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td char="." align="char" colspan="1" rowspan="1">33 (21.7%)</td><td char="." align="char" colspan="1" rowspan="1">26 (39.4%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">41 (24.7%)</td><td char="." align="char" colspan="1" rowspan="1">18 (34.6%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Liver metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.777</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.567</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td char="." align="char" colspan="1" rowspan="1">89 (58.6%)</td><td char="." align="char" colspan="1" rowspan="1">40 (60.6%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">100 (60.2%)</td><td char="." align="char" colspan="1" rowspan="1">29 (55.8%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td char="." align="char" colspan="1" rowspan="1">63 (41.4%)</td><td char="." align="char" colspan="1" rowspan="1">26 (39.4%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">66 (39.8%)</td><td char="." align="char" colspan="1" rowspan="1">23 (44.2%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Lung metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.818</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.530</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td char="." align="char" colspan="1" rowspan="1">133 (87.5%)</td><td char="." align="char" colspan="1" rowspan="1">57 (86.4%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">146 (88.0%)</td><td char="." align="char" colspan="1" rowspan="1">44 (84.6%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td char="." align="char" colspan="1" rowspan="1">19 (12.5%)</td><td char="." align="char" colspan="1" rowspan="1">9 (13.6%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">20 (12.0%)</td><td char="." align="char" colspan="1" rowspan="1">8 (15.4%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Metastatic sites</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.399</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.125</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;2</td><td char="." align="char" colspan="1" rowspan="1">127 (83.6%)</td><td char="." align="char" colspan="1" rowspan="1">52 (78.8%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">140 (84.3%)</td><td char="." align="char" colspan="1" rowspan="1">39 (75.0%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;3</td><td char="." align="char" colspan="1" rowspan="1">25 (16.4%)</td><td char="." align="char" colspan="1" rowspan="1">14 (21.2%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">26 (15.7%)</td><td char="." align="char" colspan="1" rowspan="1">13 (25.0%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ECOG PS</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.270</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;1</td><td char="." align="char" colspan="1" rowspan="1">133 (87.5%)</td><td char="." align="char" colspan="1" rowspan="1">54 (81.8%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">150 (90.4%)</td><td char="." align="char" colspan="1" rowspan="1">37 (71.2%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;2</td><td char="." align="char" colspan="1" rowspan="1">19 (12.5%)</td><td char="." align="char" colspan="1" rowspan="1">12 (18.2%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">16 (9.6%)</td><td char="." align="char" colspan="1" rowspan="1">15 (28.8%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment types</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.386</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">
<bold>0.012</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;PD-1&#8201;+&#8201;chemotherapy</td><td char="." align="char" colspan="1" rowspan="1">89 (58.6%)</td><td char="." align="char" colspan="1" rowspan="1">36 (54.5%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">104 (62.7%)</td><td char="." align="char" colspan="1" rowspan="1">21 (40.4%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;PD-1&#8201;+&#8201;targeted therapy</td><td char="." align="char" colspan="1" rowspan="1">18 (11.8%)</td><td char="." align="char" colspan="1" rowspan="1">5 (7.6%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">17 (10.2%)</td><td char="." align="char" colspan="1" rowspan="1">6 (11.5%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Others</td><td char="." align="char" colspan="1" rowspan="1">45 (29.6%)</td><td char="." align="char" colspan="1" rowspan="1">25 (37.9%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">45 (27.1%)</td><td char="." align="char" colspan="1" rowspan="1">25 (48.1%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Treatment lines</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.343</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.180</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;2</td><td char="." align="char" colspan="1" rowspan="1">113 (74.3%)</td><td char="." align="char" colspan="1" rowspan="1">53 (80.3%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">130 (78.3%)</td><td char="." align="char" colspan="1" rowspan="1">36 (69.2%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;3</td><td char="." align="char" colspan="1" rowspan="1">39 (25.7%)</td><td char="." align="char" colspan="1" rowspan="1">13 (19.7%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">36 (21.7%)</td><td char="." align="char" colspan="1" rowspan="1">16 (30.8%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">HER-2</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.360</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">&gt;&#8201;0.999</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td char="." align="char" colspan="1" rowspan="1">137 (90.1%)</td><td char="." align="char" colspan="1" rowspan="1">62 (93.9%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">151 (91.0%)</td><td char="." align="char" colspan="1" rowspan="1">48 (92.3%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td char="." align="char" colspan="1" rowspan="1">15 (9.9%)</td><td char="." align="char" colspan="1" rowspan="1">4 (6.1%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">15 (9.0%)</td><td char="." align="char" colspan="1" rowspan="1">4 (7.7%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">CEA</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.497</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">0.576</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;5</td><td char="." align="char" colspan="1" rowspan="1">73 (48.0%)</td><td char="." align="char" colspan="1" rowspan="1">35 (53.0%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">84 (50.6%)</td><td char="." align="char" colspan="1" rowspan="1">24 (46.2%)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;5</td><td char="." align="char" colspan="1" rowspan="1">79 (52.0%)</td><td char="." align="char" colspan="1" rowspan="1">31 (47.0%)</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">82 (49.4%)</td><td char="." align="char" colspan="1" rowspan="1">28 (53.8%)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec100"><title>Effect of antibiotic exposure in different time windows on patient prognosis</title><p id="Par16">After conducting Cox regression analysis for ATB exposure at various time windows, we found that ATB exposure from 60 days before to 30 days before treatment and from 30 days before to 1&#160;day before treatment did not significantly affect PFS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.965, <italic toggle="yes">P</italic>&#8201;=&#8201;0.507) or OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.953, <italic toggle="yes">P</italic>&#8201;=&#8201;0.860) in AGC patients (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). In contrast, antibiotic exposure from post-treatment to 30 days post-treatment and from 30 days post-treatment to 60 days post-treatment emerged as prognostic factors for PFS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.031, <italic toggle="yes">P</italic>&#8201;=&#8201;0.034) in AGC patients. However, these exposures had no significant effect on OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.260, <italic toggle="yes">P</italic>&#8201;=&#8201;0.479). Similar results were observed for the pATB and cATB groups. Specifically, ATB exposure from 60 days before immunotherapy to 1&#160;day before treatment had no significant effect on PFS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.598) or OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.804) in gastric cancer patients. In contrast, antibiotic exposure from treatment to 60 days after treatment was a prognostic factor for PFS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007) but it did not significantly affect OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.324). Of note, we performed further sensitivity analysis to exclude nine patients who developed severe infections that delayed anti-tumor therapy after PD-1 inhibitor treatment. Interestingly, adjusted cATB was no longer a prognostic factor for PFS in patients with advanced gastric malignancies (<italic toggle="yes">P</italic>&#8201;=&#8201;0.074).</p><p id="Par17">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Univariate Cox regression analysis of PFS and OS in patients with AGC treated with PD-1 inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">ATB exposure</th><th align="left" colspan="2" rowspan="1">PFS</th><th align="left" colspan="2" rowspan="1">OS</th></tr><tr><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">P-value</th><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">60 days before therapy to 30 days therapy treatment</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.008 (0.695&#8211;1.462)</td><td align="left" colspan="1" rowspan="1">0.965</td><td align="left" colspan="1" rowspan="1">1.013 (0.664&#8211;1.545)</td><td align="left" colspan="1" rowspan="1">0.953</td></tr><tr><td align="left" colspan="3" rowspan="1">30 days before therapy to 1&#160;day therapy treatment</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.129 (0.789&#8211;1.615)</td><td align="left" colspan="1" rowspan="1">0.507</td><td align="left" colspan="1" rowspan="1">0.963 (0.631&#8211;1.468)</td><td align="left" colspan="1" rowspan="1">0.860</td></tr><tr><td align="left" colspan="3" rowspan="1">Beginning of therapy to 30 days therapy treatment</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.535 (1.038&#8211;2.269)</td><td align="left" colspan="1" rowspan="1">
<bold>0.031</bold>
</td><td align="left" colspan="1" rowspan="1">1.294 (0.825&#8211;2.030)</td><td align="left" colspan="1" rowspan="1">0.260</td></tr><tr><td align="left" colspan="3" rowspan="1">30 days after therapy to 60 days therapy treatment</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.528 (1.030&#8211;2.268)</td><td align="left" colspan="1" rowspan="1">
<bold>0.034</bold>
</td><td align="left" colspan="1" rowspan="1">1.183 (0.743&#8211;1.885)</td><td align="left" colspan="1" rowspan="1">0.479</td></tr><tr><td align="left" colspan="1" rowspan="1">pATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.089 (0.793&#8211;1.494)</td><td align="left" colspan="1" rowspan="1">0.598</td><td align="left" colspan="1" rowspan="1">0.955 (0.661&#8211;1.379)</td><td align="left" colspan="1" rowspan="1">0.804</td></tr><tr><td align="left" colspan="1" rowspan="1">cATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.591 (1.131&#8211;2.239)</td><td align="left" colspan="1" rowspan="1">
<bold>0.007</bold>
</td><td align="left" colspan="1" rowspan="1">1.221 (0.820&#8211;1.817)</td><td align="left" colspan="1" rowspan="1">0.324</td></tr><tr><td align="left" colspan="2" rowspan="1">Adjusted cATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.400 (0.966&#8211;2.028)</td><td align="left" colspan="1" rowspan="1">0.074</td><td align="left" colspan="1" rowspan="1">1.148 (0.746&#8211;1.766)</td><td align="left" colspan="1" rowspan="1">0.530</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>HR = Hazard Ratio, CI&#8201;=&#8201;Confidence Interval</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec500"><title>Prognostic factors affecting patients&#8217; PFS and OS</title><p id="Par18">According to characteristic with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 in univariate Cox analysis, a stepwise backward method was used to include variables with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 to generate the final multivariate model. The multivariate Cox analysis showed that treatment lines (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and cATB exposure (<italic toggle="yes">P</italic>&#8201;=&#8201;0.027) were independent predictors of PFS in AGC patients receiving PD-1 inhibitors (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Furthermore, it was shown that treatment lines (<italic toggle="yes">P</italic>&#8201;=&#8201;0.004) and peritoneal metastasis (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002) were independent prognostic variables that predicted OS in AGC patients (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par19">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Cox regression analysis of PFS in AGC patients treated with PD-1 inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="left" colspan="2" rowspan="1">Univariate</th><th align="left" colspan="2" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">P-value</th><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">0.931 (0.679&#8211;1.278)</td><td align="left" colspan="1" rowspan="1">0.660</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;65</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;65</td><td align="left" colspan="1" rowspan="1">0.814 (0.595&#8211;1.114)</td><td align="left" colspan="1" rowspan="1">0.198</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Peritoneum metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">1.293 (0.936&#8211;1.786)</td><td align="left" colspan="1" rowspan="1">0.118</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">1.425 (1.052&#8211;1.932)</td><td align="left" colspan="1" rowspan="1">
<bold>0.022</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Lung metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">0.825 (0.527&#8211;1.292)</td><td align="left" colspan="1" rowspan="1">0.401</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Metastasis sites</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;2</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;3</td><td align="left" colspan="1" rowspan="1">1.183 (0.808&#8211;1.732)</td><td align="left" colspan="1" rowspan="1">0.387</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG PS</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;1</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;2</td><td align="left" colspan="1" rowspan="1">0.991 (0.652&#8211;1.506)</td><td align="left" colspan="1" rowspan="1">0.965</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment types</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">
<bold>0.004</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;PD-1&#8201;+&#8201;chemotherapy</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;PD-1&#8201;+&#8201;targeted therapy</td><td align="left" colspan="1" rowspan="1">2.131 (1.348&#8211;3.369)</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Others</td><td align="left" colspan="1" rowspan="1">1.014 (0.730&#8211;1.409)</td><td align="left" colspan="1" rowspan="1">0.934</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment lines</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;2</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;3</td><td align="left" colspan="1" rowspan="1">1.589 (1.344&#8211;1.878)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">1.550 (1.309&#8211;1.835)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">pATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.089 (0.793&#8211;1.494)</td><td align="left" colspan="1" rowspan="1">0.598</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">cATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.591 (1.131&#8211;2.239)</td><td align="left" colspan="1" rowspan="1">
<bold>0.007</bold>
</td><td align="left" colspan="1" rowspan="1">1.508 (1.067&#8211;2.132)</td><td align="left" colspan="1" rowspan="1">
<bold>0.027</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">HER-2</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative/Unknown</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">0.939 (0.544&#8211;1.623)</td><td align="left" colspan="1" rowspan="1">0.823</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">CEA</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;5</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;5</td><td align="left" colspan="1" rowspan="1">1.398 (1.035&#8211;1.888)</td><td align="left" colspan="1" rowspan="1">
<bold>0.028</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>HR = Hazard Ratio, CI&#8201;=&#8201;Confidence Interval</p></table-wrap-foot></table-wrap>
</p><p id="Par20">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Cox regression analysis of OS in AGC patients treated with PD-1 inhibitors</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="left" colspan="2" rowspan="1">Univariate</th><th align="left" colspan="2" rowspan="1">Multivariate</th></tr><tr><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">P-value</th><th align="left" colspan="1" rowspan="1">HR<sup>1</sup> (95% CI)<sup>1</sup></th><th align="left" colspan="1" rowspan="1">P-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">1.080 (0.751&#8211;1.553)</td><td align="left" colspan="1" rowspan="1">0.678</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;65</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;65</td><td align="left" colspan="1" rowspan="1">0.826 (0.578&#8211;1.179)</td><td align="left" colspan="1" rowspan="1">0.292</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Peritoneum metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">1.469 (1.017&#8211;2.122)</td><td align="left" colspan="1" rowspan="1">
<bold>0.039</bold>
</td><td align="left" colspan="1" rowspan="1">1.840 (1.250&#8211;2.710)</td><td align="left" colspan="1" rowspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">0.961 (0.681&#8211;1.355)</td><td align="left" colspan="1" rowspan="1">0.819</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Lung metastasis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">1.024 (0.630&#8211;1.665)</td><td align="left" colspan="1" rowspan="1">0.922</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Metastasis sites</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;2</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;3</td><td align="left" colspan="1" rowspan="1">1.136 (0.754&#8211;1.714)</td><td align="left" colspan="1" rowspan="1">0.541</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">ECOG PS</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;1</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;2</td><td align="left" colspan="1" rowspan="1">0.859 (0.509&#8211;1.449)</td><td align="left" colspan="1" rowspan="1">0.568</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment types</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">
<bold>0.002</bold>
</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;PD-1&#8201;+&#8201;chemotherapy</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;PD-1&#8201;+&#8201;targeted therapy</td><td align="left" colspan="1" rowspan="1">2.311 (1.403&#8211;3.808)</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Others</td><td align="left" colspan="1" rowspan="1">0.967 (0.662&#8211;1.412)</td><td align="left" colspan="1" rowspan="1">0.862</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Treatment lines</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;2</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805;&#8201;3</td><td align="left" colspan="1" rowspan="1">1.408 (1.174&#8211;1.688)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td><td align="left" colspan="1" rowspan="1">1.366 (1.103&#8211;1.692)</td><td align="left" colspan="1" rowspan="1">
<bold>0.004</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">pATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">0.955 (0.661&#8211;1.379)</td><td align="left" colspan="1" rowspan="1">0.804</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">cATB exposure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">1.221 (0.820&#8211;1.817)</td><td align="left" colspan="1" rowspan="1">0.324</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">HER-2</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Negative/Unknown</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Positive</td><td align="left" colspan="1" rowspan="1">0.887 (0.500-1.573)</td><td align="left" colspan="1" rowspan="1">0.681</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">CEA</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804;&#8201;5</td><td align="left" colspan="1" rowspan="1">1 (Reference)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;5</td><td align="left" colspan="1" rowspan="1">1.470 (1.046&#8211;2.067)</td><td align="left" colspan="1" rowspan="1">
<bold>0.026</bold>
</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>HR = Hazard Ratio, CI&#8201;=&#8201;Confidence Interval</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Survival curves analysis</title><p id="Par21">In this study, the median follow-up time for patients was 19.614 months (95% CI: 18.507&#8211;20.721). Figure&#160;<xref rid="Fig1" ref-type="fig">1</xref> shows Kaplan-Meier curves of antibiotic use on PFS and OS in AGC patients receiving PD-1 inhibitors. The use of Antibiotics was divided into two groups, with antibiotics used 60 days before (pATB) and 60 days after immune checkpoint inhibitor treatment (cATB). PFS was significantly worse in cATB exposure patients than in patients without cATB exposure (mPFS: 4.008 months, 95% CI: 2.582&#8211;5.434 vs. 6.407 months, 95% CI: 5.275&#8211;7.539, <italic toggle="yes">p</italic>&#8201;=&#8201;0.007) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). In the treatment lines&#8201;&#8804;&#8201;2, PFS (mPFS: 7.031 months, 95% CI: 5.899&#8211;8.163 vs. 2.760 months, 95% CI: 1.831&#8211;3.688, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b) and OS (mOS: 14.193 months, 95% CI: 11.600-16.786 vs. 8.214 months, 95% CI: 5.180&#8211;11.247, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>d) were significantly longer than treatment lines&#8201;&#8805;&#8201;3. Furthermore, the prognosis was poorer for individuals with positive peritoneal metastases than for those with negative ones (mOS: 9.495 months, 95% CI: 6.726&#8211;12.264, vs. 14.357 months, 95% CI: 11.840-16.875, <italic toggle="yes">p</italic>&#8201;=&#8201;0.039) (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c).</p><p id="Par22">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) of AGC patients treated with PD-1 inhibitors. (a) cATB exposure in PFS. (b) Treatment lines in PFS. (c) peritoneal metastasis in OS. (d) Treatment lines in OS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e2048" position="float" orientation="portrait" xlink:href="12672_2025_3558_Fig1_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par23">Therapeutic approaches for malignant tumors have greatly improved in recent years with the advent of immune checkpoint inhibitors, especially, PD-1 inhibitors [<xref ref-type="bibr" rid="CR16">16</xref>]. Since antibiotics are known to mainly alter the makeup of the gut microbiota, they may lessen the effectiveness of PD-1 immunotherapy [<xref ref-type="bibr" rid="CR17">17</xref>]. Notably, the effect of antibiotic exposure on PD-1 inhibitor therapy has generated significant concern and debate. However, the time-dependent effects of ATB exposure and its mechanism of action on survival in AGC patients remain poorly understood.</p><p id="Par24">Prior researchs involving PD-1 inhibitor monotherapy in non-small cell lung cancer (NSCLC) patients found that those who received antibiotics experienced notably shorter PFS and OS [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Similarly, in gastric cancer, Kim et al. pointed out that the use of antibiotics prior to immunotherapy reduces the diversity of the gut microbiota, thereby decreasing PFS and OS in gastric cancer patients [<xref ref-type="bibr" rid="CR10">10</xref>]. Conversely, other studies suggested that the use of antibiotics may not have a negative impact on the prognosis of patients receiving PD-1 inhibitor drug therapy [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. It is important to note that the prognostic significance of antibiotic exposure in cancer patients undergoing certain PD-1 inhibitor treatment regimens, especially PD-1 inhibitor combination therapy, has not been extensively studied. Therefore, we examined the effect of ATB exposure on the outcome of PD-1 inhibitor combination treatment in AGC patients.</p><p id="Par25">The question of whether exposure to antibiotics reduces the effectiveness of PD-1 inhibitor treatment is still significant and contentious. In this research, we particularly looked at the relationship between the clinical prognosis and the time of ATB exposure in 218 AGC patients receiving PD-1 inhibitors. By analyzing the impact of ATB use in different time windows on patient prognosis, our findings fill an important gap in understanding how antibiotic exposure affects the prognosis of gastric cancer patients. Specifically, we observed that pATB did not influence the prognosis of AGC patients undergoing PD-1 inhibitor combination therapy. In contrast, cATB adversely affected PFS in AGC patients (<italic toggle="yes">P</italic>&#8201;=&#8201;0.027), but no significant effect was observed on OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.324). These findings echo those of a prior study on the influence of early antibiotic exposure on immunotherapy efficacy in hepatocellular carcinoma [<xref ref-type="bibr" rid="CR21">21</xref>]. Notably, it is crucial to recognize that this study primarily focused on ICIs monotherapy. The landscape shifts significantly when antibiotics are applied in ICIs combinations. Previous studies have shown that patients with NSCLC receiving chemo-immunotherapy combinations avoid the adverse effects of antibiotics [<xref ref-type="bibr" rid="CR18">18</xref>]. This disparity underscores the divergent implications of antibiotic use in ICIs combination therapies versus ICIs monotherapy. Mechanistically, PD-1 inhibitors rely on diverse gut microbiota to activate dendritic cells and enhance tumor infiltration by CD8&#8201;+&#8201;T cells. Post-treatment use of ATBs, especially broad-spectrum agents, may deplete key bacterial taxa required for optimal anti-tumor immunity, thereby affecting the prognosis of tumor patients [<xref ref-type="bibr" rid="CR22">22</xref>]. Our study expands existing knowledge by establishing an association between antibiotic exposure and immunotherapy combinations in AGC patients. Furthermore, the independent prognostic value of the number of treatment lines of PFS (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.004) emphasized the effect of prior treatment resistance on PD-1 inhibitor efficacy. Similarly, positive peritoneal metastasis was a poor predictive factor for OS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002), which echoes the findings of Ishigami et al., who attributed it to impaired drug delivery and systemic inflammation [<xref ref-type="bibr" rid="CR23">23</xref>]. Our data extend this observation to a PD-1 inhibitor-treated cohort, suggesting that micro-environmental immunosuppression in peritoneal lesions may further limit the activity of PD-1 inhibitors. These findings highlight the need for stratified treatment strategies for AGC subgroups.</p><p id="Par26">A previous study reported that pATB led to shorter PFS and OS in gastric cancer patients receiving PD-1 therapy [<xref ref-type="bibr" rid="CR10">10</xref>], whereas our study population did not observe the effects of pATB. This discrepancy may be attributed to the following reasons: First, the two study cohort populations differed in that all patients in our cohort received PD-1 inhibitor combination therapy, whereas PD-1 monotherapy was present in the study by Kim et al. The differences suggest that combination therapy may mitigate the negative effects of antibiotics on the gut microbiota. Recent preclinical evidence has explored the effects of different immunotherapy regimens on the gut microbiota, with immunotherapy monotherapy and immunotherapy combination therapy exerting distinct effects on patients&#8217; microbiota. In patients receiving monotherapy, the abundance of certain Bacteroides species continued to increase in those with PFS&#8201;&lt;&#8201;12 months, whereas in the combination therapy group, the abundance of these species did not show significant changes [<xref ref-type="bibr" rid="CR24">24</xref>]. This finding suggests that different immunotherapy regimens may modulate the gut microbiota through distinct immune mechanisms. In addition, many of patients in Kim et al.&#8216;s study received multiple lines of prior therapy (&#8805;&#8201;4 lines), whereas our cohort included more patients receiving early treatment courses (&#8804;&#8201;2 lines). Of note, a recent Chinese cohort study also came to a similar conclusion as ours, that antibiotic use in infected GC patients treated with PD-1 inhibitors did not increase the risk of death compared to patients who did not use antibiotics [<xref ref-type="bibr" rid="CR11">11</xref>]. This also highlights the impact of cohort differences on outcomes. Finally, there were differences in the types of PD-1 inhibitors used in the two cohorts, and different types of PD-1 inhibitors may have different effects on the microbiome.</p><p id="Par27">Notably, patients with advanced cancer with poorer general conditions face an increased risk of developing infections and are more likely to undergo antibiotic therapy. The relatively poor prognosis of these patients may be a confounding factor that affects the overall prognosis [<xref ref-type="bibr" rid="CR25">25</xref>]. Upon closer examination of the reasons behind disease progression, we identified that nine AGC patients experienced varying delays in the subsequent course of treatment following cATB exposure. This treatment delay may have directly or indirectly contributed to the early progression of the disease. Subsequent sensitivity analysis excluding nine patients with delayed treatment (due to cATB-related infection) showed that cATB was no longer a predictor of PFS (<italic toggle="yes">P</italic>&#8201;=&#8201;0.074). It is worth noting that among the 9 patients, only 1 had an ECOG PS of 2, while the remaining patients had an ECOG PS of less than 2. However, 8 of the 9 patients developed severe infections and received treatment with two or more antibiotics, indicating that disease progression was due to treatment delays caused by infection rather than poor baseline ECOG PS. Therefore, the initial PFS false positives may reflect confounding factors related to clinical discontinuation. In clinical practice, clinicians often maintain the original drug regimen owing to long time intervals. This treatment persistence may not significantly alter the OS of the patients. This may explain the disparity in the prognostic impact of cATB exposure on PFS and OS in the initial analysis. Additionally, we collected data on the use of other drugs, such as corticosteroids and proton pump inhibitors, during PD-1 inhibitor combination therapy. However, these drugs did not appear to affect the prognosis of AGC patients.</p><p id="Par28">It is worth noting that specific types of antibiotic therapy can lead to specific changes in the bacterial microbiota. Previous research analyzed the effects of 144 antibiotics on gut microbiota. For example, macrolide antibiotics nearly inhibited all tested commensal bacteria, providing a potential explanation for their strong impact on gut microbiota. The authors also proposed strategies to mitigate their adverse effects on gut microbiota. This study enhances our understanding of how antibiotics influence gut microbiota [<xref ref-type="bibr" rid="CR26">26</xref>]. Previous research has shown that Streptococcus anginosus (SA) promotes tumor cell proliferation and metastasis while inhibiting the differentiation and infiltration of CD8&#8201;+&#8201;T cells. However, antibiotic treatment significantly suppresses tumor development in SA-positive mice. This suggests that antibiotics may regulate the immune microenvironment by inhibiting Streptococcus anginosus, thereby influencing the efficacy of immunotherapy [<xref ref-type="bibr" rid="CR27">27</xref>]. However, another study showed that ATB use leads to reduced gut microbiota diversity, decreased Lactobacillus casei abundance, and enrichment of circulating exhaustion-associated CD8&#8201;+&#8201;T cells, all of which are associated with poorer immunotherapy outcomes [<xref ref-type="bibr" rid="CR10">10</xref>]. This suggests that the use of antibiotics has a dual effect on the efficacy of immunotherapy.</p><p id="Par29">Despite our systematic approach to explore the impact of antibiotic exposure in different time windows on the prognosis of AGS patients treated with PD-1 inhibitors, the single-center retrospective research has some limitations. First, although we adjusted for factors such as ECOG PS and treatment lines, the retrospective design cannot rule out potential confounding factors and selection bias. Second, there is a lack of in-depth exploration of fecal microbiome data and associated mechanism. Additionally, due to the confounding effects of antibiotic use in clinical practice and the absence of uniform definition criteria, we did not perform subgroup analyses for different types, doses, and durations of antibiotics. Third, although we recorded the categories of antibiotics, this study did not consider heterogeneity in antibiotic spectrum (e.g., broad-spectrum vs. narrow-spectrum), total dose, or treatment duration, which may influence gut microbiota composition and immunotherapy efficacy. For example, broad-spectrum antibiotics may cause more severe microbial imbalance compared to narrow-spectrum antibiotics. Similarly, long-term antibiotics use may lead to sustained microbiota suppression. Future studies should establish prospective cohorts with standardized antibiotic records (including antibiotic type, dose, and duration) and incorporate microbiome sequencing data to validate the effects of antibiotics on the microbiome and immunotherapy. Finally, the study did not consider other medications that may interact with immunotherapy (e.g., corticosteroids, proton pump inhibitors). And due to the limited sample size of immunotherapy monotherapy, future studies should include cohorts receiving immunotherapy combination therapy and immunotherapy monotherapy to compare the differences in the effects of antibiotic exposure on immunotherapy between different treatment regimens. In summary, our findings require validation through further prospective, large-scale cohort studies.</p></sec><sec id="Sec13"><title>Conclusion</title><p id="Par30">In conclusion, our findings indicate that there is no evidence suggesting that exposure to antibiotics affects the long-term prognosis of AGC patients received PD-1 inhibitor combination treatment. Therefore, physicians should not delay the PD-1 inhibitor combination regimen in AGC patients who have recently received antibiotics. In the future, the effect of antibiotic exposure on PD-1 inhibitor treatment warrants further in-depth investigation through larger prospective studies.</p></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12672_2025_3558_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Additional file 1.</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Ziting Qu and Yuyan Wang contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank all the patients who participated in this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization: Kangsheng Gu; data curation: Zhikun Wang and Yan Zhang; writing&#8212;original draft: Ziting Qu and Yuyan Wang; writing&#8212;review and editing: Yiyin Zhang.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Health Research Project of Anhui Province (No. AHWJ2023A10025), the Basic and Clinical Collaborative Research Enhancement Project of Anhui Medical University (No. 2023xkjT039), and Anhui Medical University Graduate Student Research and Practice Innovation Program (No. YJS20240020).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par31">This study was conducted in accordance with the principles of the Declaration of Helsinki. This study involving human participants was approved by the Ethics Committee of Anhui Medical University (Quick-PJ 2023-14-77). Informed consent was obtained from all individual participants included in the study.</p></notes><notes id="FPar5"><title>Consent for publication</title><p id="Par32">All authors have provided their consent for publication.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par33">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#8211;49. 10.3322/caac.21660.<pub-id pub-id-type="pmid">33538338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name><name name-style="western"><surname>Chen</surname><given-names>LT</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>MH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>DY</given-names></name><name name-style="western"><surname>Oh</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chung</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet Oncol</source><year>2022</year><volume>23</volume><issue>2</issue><fpage>234</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00692-6</pub-id><pub-id pub-id-type="pmid">35030335</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234&#8211;47. 10.1016/S1470-2045(21)00692-6.<pub-id pub-id-type="pmid">35030335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(21)00692-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janjigian</surname><given-names>YY</given-names></name><name name-style="western"><surname>Shitara</surname><given-names>K</given-names></name><name name-style="western"><surname>Moehler</surname><given-names>M</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>M</given-names></name><name name-style="western"><surname>Salman</surname><given-names>P</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L</given-names></name><etal/></person-group><article-title>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial</article-title><source>Lancet (London England)</source><year>2021</year><volume>398</volume><issue>10294</issue><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00797-2</pub-id><pub-id pub-id-type="pmid">34102137</pub-id><pub-id pub-id-type="pmcid">PMC8436782</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet (London England). 2021;398(10294):27&#8211;40. 10.1016/S0140-6736(21)00797-2.<pub-id pub-id-type="pmid">34102137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00797-2</pub-id><pub-id pub-id-type="pmcid">PMC8436782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gu</surname><given-names>K</given-names></name><name name-style="western"><surname>Cang</surname><given-names>S</given-names></name><name name-style="western"><surname>Han</surname><given-names>L</given-names></name><etal/></person-group><article-title>Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial</article-title><source>JAMA</source><year>2023</year><volume>330</volume><issue>21</issue><fpage>2064</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.19918</pub-id><pub-id pub-id-type="pmid">38051328</pub-id><pub-id pub-id-type="pmcid">PMC10698618</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064&#8211;74. 10.1001/jama.2023.19918.<pub-id pub-id-type="pmid">38051328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.19918</pub-id><pub-id pub-id-type="pmcid">PMC10698618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Routy</surname><given-names>B</given-names></name><name name-style="western"><surname>Le Chatelier</surname><given-names>E</given-names></name><name name-style="western"><surname>Derosa</surname><given-names>L</given-names></name><name name-style="western"><surname>Duong</surname><given-names>CPM</given-names></name><name name-style="western"><surname>Alou</surname><given-names>MT</given-names></name><name name-style="western"><surname>Daill&#232;re</surname><given-names>R</given-names></name><etal/></person-group><article-title>Gut Microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors</article-title><source>Sci (New York NY)</source><year>2018</year><volume>359</volume><issue>6371</issue><fpage>91</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1126/science.aan3706</pub-id><pub-id pub-id-type="pmid">29097494</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill&#232;re R, et al. Gut Microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Sci (New York NY). 2018;359(6371):91&#8211;7. 10.1126/science.aan3706.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.aan3706</pub-id><pub-id pub-id-type="pmid">29097494</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Gazzaniga FS, Kasper DL. The gut Microbiome and cancer response to immune checkpoint inhibitors. J Clin Invest. 2025;135(3). 10.1172/JCI184321.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI184321</pub-id><pub-id pub-id-type="pmcid">PMC11785914</pub-id><pub-id pub-id-type="pmid">39895632</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derosa</surname><given-names>L</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>MD</given-names></name><name name-style="western"><surname>Spaziano</surname><given-names>M</given-names></name><name name-style="western"><surname>Halpenny</surname><given-names>D</given-names></name><name name-style="western"><surname>Fidelle</surname><given-names>M</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer</article-title><source>Ann Oncol</source><year>2018</year><volume>29</volume><issue>6</issue><fpage>1437</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy103</pub-id><pub-id pub-id-type="pmid">29617710</pub-id><pub-id pub-id-type="pmcid">PMC6354674</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018;29(6):1437&#8211;44. 10.1093/annonc/mdy103.<pub-id pub-id-type="pmid">29617710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/annonc/mdy103</pub-id><pub-id pub-id-type="pmcid">PMC6354674</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wada</surname><given-names>A</given-names></name><name name-style="western"><surname>Enokida</surname><given-names>T</given-names></name><name name-style="western"><surname>Okano</surname><given-names>S</given-names></name><name name-style="western"><surname>Sato</surname><given-names>M</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck</article-title><source>Eur J Cancer</source><year>2023</year><volume>184</volume><fpage>30</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2023.02.011</pub-id><pub-id pub-id-type="pmid">36898232</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wada A, Enokida T, Okano S, Sato M, Tanaka H, Ueda Y, et al. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2023;184:30&#8211;8. 10.1016/j.ejca.2023.02.011.<pub-id pub-id-type="pmid">36898232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejca.2023.02.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eng</surname><given-names>L</given-names></name><name name-style="western"><surname>Sutradhar</surname><given-names>R</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kaliwal</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><issue>17</issue><fpage>3122</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.00074</pub-id><pub-id pub-id-type="pmid">36827626</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y, et al. Impact of antibiotic exposure before immune checkpoint inhibitor treatment on overall survival in older adults with cancer: a population-based study. J Clin Oncol. 2023;41(17):3122&#8211;34. 10.1200/JCO.22.00074.<pub-id pub-id-type="pmid">36827626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.22.00074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>CG</given-names></name><name name-style="western"><surname>Koh</surname><given-names>JY</given-names></name><name name-style="western"><surname>Shin</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Shin</surname><given-names>JH</given-names></name><name name-style="western"><surname>Hong</surname><given-names>M</given-names></name><name name-style="western"><surname>Chung</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut Microbiome and systemic immune response</article-title><source>Cell Rep Med</source><year>2023</year><volume>4</volume><issue>11</issue><fpage>101251</fpage><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101251</pub-id><pub-id pub-id-type="pmid">37890486</pub-id><pub-id pub-id-type="pmcid">PMC10694627</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kim CG, Koh JY, Shin SJ, Shin JH, Hong M, Chung HC, et al. Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut Microbiome and systemic immune response. Cell Rep Med. 2023;4(11):101251. 10.1016/j.xcrm.2023.101251.<pub-id pub-id-type="pmid">37890486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2023.101251</pub-id><pub-id pub-id-type="pmcid">PMC10694627</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name><name name-style="western"><surname>Lian</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy</article-title><source>Oncologist</source><year>2025</year><volume>30</volume><issue>2</issue><fpage>oyae362</fpage><pub-id pub-id-type="doi">10.1093/oncolo/oyae362</pub-id><pub-id pub-id-type="pmid">40036772</pub-id><pub-id pub-id-type="pmcid">PMC11879193</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Zhang F, Ding Z, Lian Y, et al. Prophylactic antibiotic use is associated with better clinical outcomes in gastric cancer patients receiving immunotherapy. Oncologist. 2025;30(2):oyae362. 10.1093/oncolo/oyae362.<pub-id pub-id-type="pmid">40036772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/oncolo/oyae362</pub-id><pub-id pub-id-type="pmcid">PMC11879193</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palleja</surname><given-names>A</given-names></name><name name-style="western"><surname>Mikkelsen</surname><given-names>KH</given-names></name><name name-style="western"><surname>Forslund</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Recovery of gut microbiota of healthy adults following antibiotic exposure</article-title><source>Nat Microbiol</source><year>2018</year><volume>3</volume><issue>11</issue><fpage>1255</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0257-9</pub-id><pub-id pub-id-type="pmid">30349083</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Palleja A, Mikkelsen KH, Forslund SK, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255&#8211;65. 10.1038/s41564-018-0257-9.<pub-id pub-id-type="pmid">30349083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-018-0257-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Modi</surname><given-names>SR</given-names></name><name name-style="western"><surname>Collins</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Relman</surname><given-names>DA</given-names></name></person-group><article-title>Antibiotics and the gut microbiota</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><issue>10</issue><fpage>4212</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1172/JCI72333</pub-id><pub-id pub-id-type="pmid">25271726</pub-id><pub-id pub-id-type="pmcid">PMC4191029</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124(10):4212&#8211;8. 10.1172/JCI72333.<pub-id pub-id-type="pmid">25271726</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI72333</pub-id><pub-id pub-id-type="pmcid">PMC4191029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaucher</surname><given-names>L</given-names></name><name name-style="western"><surname>Adda</surname><given-names>L</given-names></name><name name-style="western"><surname>S&#233;journ&#233;</surname><given-names>A</given-names></name><name name-style="western"><surname>Joachim</surname><given-names>C</given-names></name><name name-style="western"><surname>Guillaume</surname><given-names>C</given-names></name><name name-style="western"><surname>Poulet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors</article-title><source>Ther Adv Med Oncol</source><year>2021</year><volume>13</volume><fpage>17588359211000591</fpage><pub-id pub-id-type="doi">10.1177/17588359211000591</pub-id><pub-id pub-id-type="pmid">33796151</pub-id><pub-id pub-id-type="pmcid">PMC7968039</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Gaucher L, Adda L, S&#233;journ&#233; A, Joachim C, Guillaume C, Poulet C, et al. Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol. 2021;13:17588359211000591. 10.1177/17588359211000591.<pub-id pub-id-type="pmid">33796151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17588359211000591</pub-id><pub-id pub-id-type="pmcid">PMC7968039</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greally</surname><given-names>M</given-names></name><name name-style="western"><surname>Chou</surname><given-names>JF</given-names></name><name name-style="western"><surname>Chatila</surname><given-names>WK</given-names></name><name name-style="western"><surname>Margolis</surname><given-names>M</given-names></name><name name-style="western"><surname>Capanu</surname><given-names>M</given-names></name><name name-style="western"><surname>Hechtman</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>20</issue><fpage>6160</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-3603</pub-id><pub-id pub-id-type="pmid">31337644</pub-id><pub-id pub-id-type="pmcid">PMC6905384</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Greally M, Chou JF, Chatila WK, Margolis M, Capanu M, Hechtman JF, et al. Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clin Cancer Res. 2019;25(20):6160&#8211;9. 10.1158/1078-0432.CCR-18-3603.<pub-id pub-id-type="pmid">31337644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-18-3603</pub-id><pub-id pub-id-type="pmcid">PMC6905384</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Goswami</surname><given-names>S</given-names></name><name name-style="western"><surname>Raychaudhuri</surname><given-names>D</given-names></name><name name-style="western"><surname>Siddiqui</surname><given-names>BA</given-names></name><name name-style="western"><surname>Singh</surname><given-names>P</given-names></name><name name-style="western"><surname>Nagarajan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Immune checkpoint therapy-current perspectives and future directions</article-title><source>Cell</source><year>2023</year><volume>186</volume><issue>8</issue><fpage>1652</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2023.03.006</pub-id><pub-id pub-id-type="pmid">37059068</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652&#8211;69. 10.1016/j.cell.2023.03.006.<pub-id pub-id-type="pmid">37059068</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2023.03.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Macandog ADG, Catozzi C, Capone M, Nabinejad A, Nanaware PP, Liu S et al. Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024; 32(11):2004&#8211;2018.e2009. 10.1016/j.chom.2024.10.006<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2024.10.006</pub-id><pub-id pub-id-type="pmcid">PMC11629153</pub-id><pub-id pub-id-type="pmid">39481388</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis DL, Aerts JG, et al. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021. 10.1136/jitc-2021-002421.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jitc-2021-002421</pub-id><pub-id pub-id-type="pmcid">PMC8031700</pub-id><pub-id pub-id-type="pmid">33827906</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chalabi</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>A</given-names></name><name name-style="western"><surname>Nagarkar</surname><given-names>DR</given-names></name><name name-style="western"><surname>Dhawahir Scala</surname><given-names>A</given-names></name><name name-style="western"><surname>Gandara</surname><given-names>DR</given-names></name><name name-style="western"><surname>Rittmeyer</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy of chemotherapy and Atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials</article-title><source>Ann Oncol</source><year>2020</year><volume>31</volume><issue>4</issue><fpage>525</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.01.006</pub-id><pub-id pub-id-type="pmid">32115349</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and Atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525&#8211;31. 10.1016/j.annonc.2020.01.006.<pub-id pub-id-type="pmid">32115349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2020.01.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortellini</surname><given-names>A</given-names></name><name name-style="western"><surname>Ricciuti</surname><given-names>B</given-names></name><name name-style="western"><surname>Facchinetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Alessi</surname><given-names>JVM</given-names></name><name name-style="western"><surname>Venkatraman</surname><given-names>D</given-names></name><name name-style="western"><surname>Dall&#8217;Olio</surname><given-names>FG</given-names></name><etal/></person-group><article-title>Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy</article-title><source>Ann Oncol</source><year>2021</year><volume>32</volume><issue>11</issue><fpage>1391</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.08.1744</pub-id><pub-id pub-id-type="pmid">34400292</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall&#8217;Olio FG, et al. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021;32(11):1391&#8211;9. 10.1016/j.annonc.2021.08.1744.<pub-id pub-id-type="pmid">34400292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.annonc.2021.08.1744</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fessas</surname><given-names>P</given-names></name><name name-style="western"><surname>Naeem</surname><given-names>M</given-names></name><name name-style="western"><surname>Pinter</surname><given-names>M</given-names></name><name name-style="western"><surname>Marron</surname><given-names>TU</given-names></name><name name-style="western"><surname>Szafron</surname><given-names>D</given-names></name><name name-style="western"><surname>Balcar</surname><given-names>L</given-names></name><etal/></person-group><article-title>Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma</article-title><source>Liver Cancer</source><year>2021</year><volume>10</volume><issue>6</issue><fpage>583</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1159/000519108</pub-id><pub-id pub-id-type="pmid">34950181</pub-id><pub-id pub-id-type="pmcid">PMC8647090</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, et al. Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma. Liver Cancer. 2021;10(6):583&#8211;92. 10.1159/000519108.<pub-id pub-id-type="pmid">34950181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000519108</pub-id><pub-id pub-id-type="pmcid">PMC8647090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nan</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yue</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Fasting-mimicking diet-enriched bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8(+) T cells</article-title><source>Gut</source><year>2025</year><pub-id pub-id-type="doi">10.1136/gutjnl-2024-333020</pub-id><pub-id pub-id-type="pmid">39870395</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Nan K, Zhong Z, Yue Y, Shen Y, Zhang H, Wang Z, et al. Fasting-mimicking diet-enriched bifidobacterium pseudolongum suppresses colorectal cancer by inducing memory CD8(+) T cells. Gut. 2025. 10.1136/gutjnl-2024-333020.<pub-id pub-id-type="pmid">39870395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2024-333020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>D</given-names></name><name name-style="western"><surname>Kodera</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fukushima</surname><given-names>R</given-names></name><name name-style="western"><surname>Morita</surname><given-names>M</given-names></name><name name-style="western"><surname>Fushida</surname><given-names>S</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>N</given-names></name><etal/></person-group><article-title>Phase II study of intraperitoneal administration of Paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis</article-title><source>Ann Surg Oncol</source><year>2024</year><volume>31</volume><issue>2</issue><fpage>735</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1245/s10434-023-14240-6</pub-id><pub-id pub-id-type="pmid">37952018</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Kobayashi D, Kodera Y, Fukushima R, Morita M, Fushida S, Yamashita N, et al. Phase II study of intraperitoneal administration of Paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Ann Surg Oncol. 2024;31(2):735&#8211;43. 10.1245/s10434-023-14240-6.<pub-id pub-id-type="pmid">37952018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-023-14240-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bj&#246;rk</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bolte</surname><given-names>LA</given-names></name><name name-style="western"><surname>Maltez Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Lee</surname><given-names>KA</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>N</given-names></name><name name-style="western"><surname>Wind</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Longitudinal gut Microbiome changes in immune checkpoint blockade-treated advanced melanoma</article-title><source>Nat Med</source><year>2024</year><volume>30</volume><issue>3</issue><fpage>785</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-02803-3</pub-id><pub-id pub-id-type="pmid">38365950</pub-id><pub-id pub-id-type="pmcid">PMC10957474</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bj&#246;rk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT, et al. Longitudinal gut Microbiome changes in immune checkpoint blockade-treated advanced melanoma. Nat Med. 2024;30(3):785&#8211;96. 10.1038/s41591-024-02803-3.<pub-id pub-id-type="pmid">38365950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-024-02803-3</pub-id><pub-id pub-id-type="pmcid">PMC10957474</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poizeau</surname><given-names>F</given-names></name><name name-style="western"><surname>Dupuy</surname><given-names>A</given-names></name></person-group><article-title>Analyzing the impact of exposure to antibiotics on immune checkpoint inhibitor efficacy: stop at a methodological checkpoint</article-title><source>J Clin Oncol</source><year>2023</year><volume>41</volume><issue>32</issue><fpage>5072</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1200/JCO.23.00730</pub-id><pub-id pub-id-type="pmid">37611217</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Poizeau F, Dupuy A. Analyzing the impact of exposure to antibiotics on immune checkpoint inhibitor efficacy: stop at a methodological checkpoint. J Clin Oncol. 2023;41(32):5072&#8211;3. 10.1200/JCO.23.00730.<pub-id pub-id-type="pmid">37611217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.23.00730</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maier</surname><given-names>L</given-names></name><name name-style="western"><surname>Goemans</surname><given-names>CV</given-names></name><name name-style="western"><surname>Wirbel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Unravelling the collateral damage of antibiotics on gut bacteria</article-title><source>Nature</source><year>2021</year><volume>599</volume><issue>7883</issue><fpage>120</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03986-2</pub-id><pub-id pub-id-type="pmid">34646011</pub-id><pub-id pub-id-type="pmcid">PMC7612847</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Maier L, Goemans CV, Wirbel J, et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature. 2021;599(7883):120&#8211;4. 10.1038/s41586-021-03986-2.<pub-id pub-id-type="pmid">34646011</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03986-2</pub-id><pub-id pub-id-type="pmcid">PMC7612847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Characterization of the landscape of the intratumoral microbiota reveals that Streptococcus anginosus increases the risk of gastric cancer initiation and progression</article-title><source>Cell Discov</source><year>2024</year><volume>10</volume><issue>1</issue><fpage>117</fpage><pub-id pub-id-type="doi">10.1038/s41421-024-00746-0</pub-id><pub-id pub-id-type="pmid">39587089</pub-id><pub-id pub-id-type="pmcid">PMC11589709</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Yuan L, Pan L, Wang Y, et al. Characterization of the landscape of the intratumoral microbiota reveals that Streptococcus anginosus increases the risk of gastric cancer initiation and progression. Cell Discov. 2024;10(1):117. 10.1038/s41421-024-00746-0. Published 2024 Nov 26.<pub-id pub-id-type="pmid">39587089</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41421-024-00746-0</pub-id><pub-id pub-id-type="pmcid">PMC11589709</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>